Current Report Filing (8-k)
February 12 2021 - 11:36AM
Edgar (US Regulatory)
0000318306
false
0000318306
2021-02-12
2021-02-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): February 12, 2021
ABEONA
THERAPEUTICS INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-15771
|
|
83-0221517
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
1330
Avenue of the Americas, 33rd Floor,
New
York, NY 10019
(Address
of principal executive offices) (Zip Code)
(646)
813-4712
(Registrant’s telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of Each Class
|
|
Trading
Symbol
|
|
Name
of each exchange on which registered
|
Common
Stock, $0.01 par value
|
|
ABEO
|
|
Nasdaq
Capital Markets
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01.
|
Regulation
FD.
|
On
February 12, 2021, Abeona Therapeutics Inc. issued a press release entitled “New Positive Phase 1/2 Interim Data Presented
at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment
with Abeona’s ABO-102 Gene Therapy.” The full text of the press release is included as Exhibit 99.1 to this Current
Report on Form 8-K and is incorporated herein by reference.
Item
9.01
|
Financial
Statements and Exhibits.
|
(d)
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Abeona
Therapeutics Inc.
|
|
(Registrant)
|
|
|
|
|
By:
|
/s/
Brendan M. O’Malley
|
|
Name:
|
Brendan
M. O’Malley
|
|
Title:
|
Corporate
Secretary
|
Date:
February 12, 2021
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Jul 2023 to Jul 2024